Update of the Consensus of the Spanish Society of Rheumatology on biological therapy in rheumatoid arthritis;III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide

Reumatologia Clinica

Volumn 2, Issue SPEC. ISS. 2, 2006, Pages 52-59

  Rodríguez Valverde, Vicente ^a   Cáliz Cáliz, Rafael ^a   Álvaro Gracia Álvaro, José M ^a   Marenco de la Fuente, José L ^a   Mulero Mendoza, Juan ^a   Tornero Molina, Jesús ^a   Andreu Sanchez J L ^a   Ballina Garcia F J ^a   Batlle Gualda, E ^a   Canete Crespillo J D ^a   Carbonell Abello J ^a   Carreno Perez L ^a   Figueroa Pedrosa, M ^a   Gomez Reino Carnota J ^a   Gonzalez Garcia T ^a   Laffon Roca, A ^a   Martin Mola E ^a   Pascual Gomez E ^a   Sanmarti Sala R ^a   Salazar Vallinas, J M ^a   Valverde Garcia J ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BCG VACCINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDOXINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAMPICIN; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

APLASTIC ANEMIA; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BIOLOGICAL THERAPY; CLINICAL EXAMINATION; COCCIDIA; COCCIDIOIDOMYCOSIS; CONSENSUS DEVELOPMENT; DISEASE ACTIVITY; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; HEART FAILURE; HEPATITIS C; HISTOPLASMA; HISTOPLASMOSIS; HUMAN; JOINT RADIOGRAPHY; LEUKOPENIA; LISTERIA; LISTERIOSIS; MEDICAL SOCIETY; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SATISFACTION; PHYSICAL CAPACITY; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SPAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 33750884080     PISSN: 1699258X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1699-258X(06)73022-4     Document Type: Article

References (57)

1. Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis. 2001;60:1040-5.
2. Lard LR, Visser H, Speyer I, Van der Horst-Bruinsman IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001;111:446-51.
3. Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with very early rheumatoid arthritis. Rheumatolology. 2004;43:906-14.
4. Rodríguez-Valverde V, Álvaro-Gracia JM, Andreu JL, Batlle E, Tornero JL. Segunda actualización del Consenso de la Sociedad Española de Reumatología sobre la Terapia Biológica en la Artritis Reumatoide. Rev Esp Reumatol. 2004;31:394-401.
5. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleichsmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9.
6. Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med. 2000;343:1594-602.
7. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara ChA, et al. Adalimumab, a fully Human anti-tumor necrosis factor monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum. 2003;48:35-45.
8. Bathon JM, Martin RW, Fleischman RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-93.
9. St. Clair EW, Van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum. 2004;50:3432-43.
10. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R, et al. The PREMIER study. A multicenter randomized double-blind clinical trial of combination therapy with adalimuumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2004;54:26-37.
11. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063-74.
12. Kalden JR, Antoni C, Alvaro-Gracia JM, Combe B, Emery P, Kremer JM, et al. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol. 2005;32:1620-31.
13. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:614-24.
14. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52:1794-803.
15. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med. 2005;201:1355-9.
16. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-81.
17. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:2263-71
18. Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2005; 32: 2109-15.
19. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114-23.
20. Esteve-Vives J, Batlle-Gualda E, Reig A, Grupo para la Adaptación del HAQa La Población Española. Spanish version of the Health Assessment Questionnaire (HAQ): reliability, validity and transcultural equivalency. J Rheumatol. 1993;20:2116-22.
21. Batlle-Gualda E, Chalmeta Verdejo I. Calidad de vida en la artritis reumatoide. Rev Esp Reumatol. 2002; Supl 1:9-21.
22. Van der Heijde DM, Dankert T, Nieman F, Rau R, Boers M. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology. 1999;38:941-7.
23. Prevoo MLL, Van't Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte BA, Van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum. 1995;38:44-8.
24. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology. 2001;40:1211-20.
25. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis (review). Arhritis Rheum. 2003;48:1771-4.
26. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9.
27. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, Van Zeben D, Kersten PJSM, Hazes JMW, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381-90.
28. Smolen JS, Van der Heijde DM, St.Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab. Arthritis Rheum. 2006;54:702-10.
29. Brocq O, Plubel Y, Breuil V, Grisot C, Flory P, Mousnier A, et al. Etanercept - infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNF. alpha. Presse Med. 2002;31:1836-9.
30. Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol. 2004;31:1098-102.
31. Vollenhoven RF, Gullstrom E, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: Data from the Stockholm TNF registry. Arthritis Rheum. 2001;44 Suppl:S82.
32. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol. 2004;31:107-9.
33. Esteve M, Saro C, González-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53:1363-5.
34. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078-82.
35. Zein NN. Etanercept Study Group Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42:315-22.
36. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor therapy. Arthritis Rheum. 2003;48:3013-22.
37. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2004;33:283-8.
38. Carmona L, Gómez Reino J, González R. Registro español de acontecimientos adversos en enfermedades reumáticas (BIOBADASER). Informe de la situación a 14 Enero 2005. Reumatol Clin. 2005;1:95-111.
39. Listín J, Strangfeld A, Kary S, Rau R, Von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403-12.
40. Keane J, Gershon S, Wise RP, Mirabil-Levens E, Kasznica J, Schwiterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-104.
41. Gomez-Reino JJ, Carmona L, Rodriguez-Valverde V, Martin-Mola E, Moreno C, et al, on behalf of the BIOBADASER Group. An active surveillance of rheumatoid arthritis patients treated with tumor necrosis factor inhibitors indicates significant tuberculosis risk increase. Arthritis Rheum. 2003;48:2122-7.
42. Grupo de Trabajo sobre Tuberculosis. Consenso national para el control de la tuberculosis en España. Med Clin (Barc). 1992;98:24-31.
43. Grupo de Trabajo del área TIR de SEPAR. Recomendaciones SEPAR. Normativa sobre la preventión de la tuberculosis. Arch Bronconeumol. 2002;38:441-51.
44. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-47 (update 2001; 164: 1319-1320.)
45. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766-72.
46. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-5.
47. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with anti tumor necrosis factor α-neutralizing agents. Arthritis Rheum. 2003; 48:319-24.
48. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Eng J Med. 2001;344:1099-100.
49. Lee JH, Slifman NR, Gherson SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor nerosis factor α antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-70.
50. Bergstrom L, Yocum DE, Tesser J, Miller M, Lisse JR, Gluck O. Coccidiomycosis (valley fever) occurring during infliximab therapy. Arthritis Rheum. 2002;46 Suppl 9:S169.
51. Joven BE, Garcia Gonzalez AJ, Ruiz T, Moreno E. Pregnancy in women receiving anti-TNF-alpha therapy. Experience in Spain. Arthritis Rheum. 2005;49 Suppl 9:S884.
52. Antoni CE, Furst DE, Manger B, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease or rheumatoid arthritis. Artrhitis Rheum. 2001;44 Suppl:S152.
53. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sanberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor a therapy for infflammatory arthritides. Arthritis Rheum. 2001;44:2862-9.
54. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740-51.
55. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699-703.
56. Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004;63:1538-43.
57. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456-73.